129
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Assessment of current clinical practices for major depression in Japan using a web-based questionnaire

&
Pages 2821-2832 | Published online: 01 Oct 2019

References

  • Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119–138. doi:10.1146/annurev-publhealth-031912-11440923514317
  • Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry. 2010;9(3):155–161. doi:10.1002/wps.2010.9.issue-320975857
  • Okumura Y, Higuchi T. Cost of depression among adults in Japan. Prim Care Companion CNS Disord. 2011;13(3):PCC.10m01082. doi:10.4088/PCC.10m01072
  • Sato S, Yeh TL. Challenges in treating patients with major depressive disorder: the impact of biological and social factors. CNS Drugs. 2013;27(Suppl 1):S5–S10. doi:10.1007/s40263-012-0028-823712795
  • Furukawa TA, Kitamura T, Takahashi K. Treatment received by depressed patients in Japan and its determinants: naturalistic observation from a multi-center collaborative follow-up study. J Affect Disord. 2000;60(3):173–179. doi:10.1016/S0165-0327(99)00175-511074105
  • Ishikawa H, Kawakami N, Kessler RC, World Mental Health Japan Survey C. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan: results from the final dataset of World Mental Health Japan Survey. Epidemiol Psychiatr Sci. 2016;25(3):217–229. doi:10.1017/S204579601500056626148821
  • Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11):e1001547. doi:10.1371/journal.pmed.100154724223526
  • World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization; 2017 Available from: http://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf. Accessed 1015, 2018.
  • Ho SC, Chong HY, Chaiyakunapruk N, Tangiisuran B, Jacob SA. Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: a systematic review. J Affect Disord. 2016;193:1–10. doi:10.1016/j.jad.2015.12.02926748881
  • Alekhya P, Sriharsha M, Venkata Ramudu R, et al. Adherence to antidepressant therapy: sociodemographic factor wise distribution. Int J Pharm Clin Res. 2015;7(3):180–184.
  • Martín Vázquez M, García-Toro M, Campoamor F, Pareja A.Uso de los tratamientos antidepresivos. La percepción del paciente [Use of antidepressant treatments. Patient perception]. Actas Esp Psiquiatr. 2015;37(5):276–281. Spanish.
  • Martín Vázquez M, García-Toro M, Campoamor F, et al. Use and results of antidepressant treatment: patients’ perception. Curr Drug Ther. 2011;6(4):271–277. doi:10.2174/157488511798109619
  • Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9(5–6):41–46.22808448
  • Tamburrino MB, Nagel RW, Chahal MK, Lynch DJ. Antidepressant medication adherence: a study of primary care patients. Prim Care Companion J Clin Psychiatry. 2009;11(5):205–211. doi:10.4088/PCC.08m0069419956457
  • Pompili M, Venturini P, Palermo M, et al. Mood disorders medications: predictors of nonadherence - review of the current literature. Expert Rev Neurother. 2013;13(7):809–825. doi:10.1586/14737175.2013.81197623898852
  • Lam RW, Kennedy SH, McLntyre RS, Khullar A. Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment. Can J Psychiatry. 2014;59(12):649–654. doi:10.1177/07067437140590120625702365
  • MacQueen GM, Memedovich KA. Cognitive dysfunction in major depression and bipolar disorder: assessment and treatment options. Psychiatry Clin Neurosci. 2017;71(1):18–27. doi:10.1111/pcn.2017.71.issue-127685435
  • Papakostas GI, Ionescu DF. Updates and trends in the treatment of major depressive disorder. J Clin Psychiatry. 2014;75(12):1419–1421. doi:10.4088/JCP.14ac0961025551237
  • Hammer-Helmich L, Haro JM, Jonsson B, et al. Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. Neuropsychiatr Dis Treat. 2018;14:239–249. doi:10.2147/NDT.S14609829386897
  • El Hammi E, Samp J, Remuzat C, et al. Difference of perceptions and evaluation of cognitive dysfunction in major depressive disorder patients across psychiatrists internationally. Ther Adv Psychopharmacol. 2014;4(1):22–29. doi:10.1177/204512531350794624490027
  • Knight MJ, Air T, Baune BT. The role of cognitive impairment in psychosocial functioning in remitted depression. J Affect Disord. 2018;235:129–134. doi:10.1016/j.jad.2018.04.05129655074
  • Knight MJ, Baune BT. Executive function and spatial cognition mediate psychosocial dysfunction in major depressive disorder. Front Psychiatry. 2018;9:539. doi:10.3389/fpsyt.2018.0053930420817
  • Knight MJ, Fourrier C, Lyrtzis E, et al. Cognitive deficits in the THINC-integrated tool (THINC-it) are associated with psychosocial dysfunction in patients with major depressive disorder. J Clin Psychiatry. 2018;80(1):18m12472. doi:10.4088/JCP.18m12472
  • Iga J-I, Uchiyama M, Ohmori T, et al. The Japanese Society of Mood Disorders Treatment Guideline. Tokyo: The Japanese Society of Mood Disorders Treatment; 2016 Available from: http://www.secretariat.ne.jp/jsmd/mood_disorder/img/160731.pdf. Accessed 1015, 2018.
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington (DC): American Psychiatric Publishing; 2013.
  • Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560. doi:10.1177/070674371665941727486148
  • National Institute for Health and Care Excellence. Depression in adults: recognition and management. 2018 Available from: https://www.nice.org.uk/guidance/cg90. Accessed 1015, 2018.
  • Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Okamoto S. Prospective epidemiological research on functioning outcomes related to major depressive disorder in Japan (PERFORM-J): protocol for a prospective cohort study. JMIR Res Protoc. 2018;7(6):e161. doi:10.2196/resprot.968229941418
  • Ragguett RM, Cha DS, Kakar R, Rosenblat JD, Lee Y, McIntyre RS. Assessing and measuring cognitive function in major depressive disorder. Evid Based Ment Health. 2016;19(4):106–109. doi:10.1136/eb-2016-10245627935809
  • Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat. 2012;2012:630206.22611491
  • Chokka P, Bougie J, Rampakakis E, Proulx J. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2018;24:1–10.
  • Liu X, Jiang K. Why is diagnosing MDD challenging? Shanghai Arch Psychiatry. 2016;28(6):343–345.28638210
  • Gilmour G, Porcelli S, Bertaina-Anglade V, et al. Relating constructs of attention and working memory to social withdrawal in Alzheimer’s disease and schizophrenia: issues regarding paradigm selection. Neurosci Biobehav Rev. 2019;97:47–69.30399355
  • Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory study. J Affect Disord. 2018;229:421–428. doi:10.1016/j.jad.2017.12.05629331703
  • Jaeger J. Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol. 2018;38(5):513–519. doi:10.1097/JCP.000000000000094130124583
  • Progress in Mind - Psichiatry & Neurology Resource Center. THINC-it® physician guide. 2017 Available from: https://progress.im/en/content/thinc-it%C2%AE-physician-guide. Accessed 726, 2019.
  • Harrison JE, Barry H, Baune BT, et al. Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: a psychometric exploration in healthy volunteers. Int J Methods Psychiatr Res. 2018;27(3):e1736. doi:10.1002/mpr.173630088298
  • McIntyre RS, Best MW, Bowie CR, et al. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry. 2017;78(7):873–881. doi:10.4088/JCP.16m1132928858441
  • Ministry of Health Labour and Welfare Japan. Supplementary material: HDS-R evaluation sheet and supplementary explanation on the index of stratification [Japanese]. 2009 Available from: https://www.mhlw.go.jp/topics/2009/05/dl/tp0501-sankou7-2.pdf. Accessed 117, 2019.
  • Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.1202204
  • Tabuse H, Kalali A, Azuma H, et al. The new GRID Hamilton Rating Scale for Depression demonstrates excellent inter-rater reliability for inexperienced and experienced raters before and after training. Psychiatry Res. 2007;153(1):61–67. doi:10.1016/j.psychres.2006.07.00417445908
  • Naganuma H. Mood disorders: Manic episode [Japanese]. Rinsho Seishin Igaku. 1999;28(Suppl):128–134.
  • Japanese Society of Neurology. Guidelines for Neurological Examination. Tokyo: Japanese Society of Neurology; 2002 Available from: https://www.neurology-jp.org/news/news_20080715_01.html. Accessed 1115, 2018.